For the benefit of patients

We are a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

Read more

We are committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).

News

Jul 01. 2019
Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA) to include patients with FGFR2 gene mutations or amplifications
Read more Download
Jun 03. 2019
Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting
Read more Download
May 02. 2019
Basilea's partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada
Read more Download
Apr 12. 2019
Basilea reports isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Read more Download

 

News Archive

Annual Report 2018

Download English
Download German

Report Archive

CEO Statement

For the benefit of patients around the world, we are continuing to establish Cresemba and Zevtera as truly global brands. In addition, by strengthening our pre-clinical and clinical oncology pipeline, we aim to become a leading provider of innovative cancer therapies in the future.

Facts & Figures